LIPID:B2
*Based on experimental studies carried out by Pierre Fabre Laboratories
XeraCalm
XERACALM A.D. – Lipid-Replenishing Balm
XeraCalm
Strengthens the skin barrier - Soothes itching - Soothes - Spaces flare-ups of dryness*
A TRIPLE EFFECTIVENESS treatment that improves, from the first month of use, the quality of life of very dry to atopic, itchy skin.
REPLENISHES THE SKIN FOR 48 HOURS*
A TRIPLE EFFECTIVENESS treatment that improves, from the first month of use, the quality of life of very dry to atopic, itchy skin.
REPLENISHES THE SKIN FOR 48 HOURS*
Usable by From birth - Pregnant women - People undergoing anti-cancer treatment or post-treatment
Skin type Dry skin prone to atopic eczema - Dry skin - Sensitive skin
Need Nourishment - Anti-scratch - Apaisement
Made in France
EMERGENCY Very dry to atopic skin, prone to itching? XERACALM AD balm reinvents itself and enhances its effectiveness.
This high-tolerance treatment rebalances the microbiome and restores the skin barrier, thanks to a new combo of cutting-edge active ingredients:
• I-MODULIA®, an optimized version of our patented anti-itchy active ingredient, targets the imbalances responsible for discomfort and dryness at the heart of the microbiome.
• The LIPID:B2 complex stimulates the synthesis of ceramides, which are essential for skin protection.
Result: the skin is soothed immediately... And for 6 months**!
Fragrance-free, non-comedogenic and sterilely packaged, XERACALM AD balm guarantees maximum effectiveness, safety and tolerance, even on the most sensitive skin or skin weakened by specific oncological/dermatological treatments. From birth.
A lipid-replenishing treatment that soothes itchy sensations due to dry skin.
• TRIPLE EFFICACY: Immediate soothing | Anti-itch*** Dermatologically and pediatricially tested.
• ANTI-ITCHING: a recognized effectiveness in the management of atopic eczema ("Emollient PLUS" category)
• SOOTHING: immediate and for 6 months***.
• RELIPIDIAN: thanks to a new patented nutrient complex, highly concentrated in fatty acids.
*Instrumental test, 2 applications per day for 7 days, 20 subjects
**Clinical scoring, 2 applications per day for 6 months, 64 subjects, limits the risk of recurrence of flare-ups of intense dryness.
Topical formula composed of excipients and additional non-drug active ingredients*. Recognized by the European Dermatology Forum - Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis), 2018.
Clinical scoring (SCORAD), 64 subjects, 2 applications per day for 6 months.